This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Cao, L. Articles by Tang, W. Search for Related Content PubMed PubMed Citation Articles by Cao, L. Articles by Tang, W. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information CPR Hazardous Substances DB EPINEPHRINE VASOPRESSIN Social Bookmarking                         What's this?

Vasopressor Agents for Cardiopulmonary Resuscitation

The Institute of Critical Care Medicine, Palm Springs, California; Los Angeles, California

Max Harry Weil, MD, PhD

Shijie Sun, MD

Wanchun Tang, MD

The Institute of Critical Care Medicine, Palm Springs, California, Los Angeles, California; Keck School of Medicine of the University of Southern California, Los Angeles, California

The primary goal of cardiopulmonary resuscitation is to reestablish blood flow to vital organs until spontaneous circulation is restored. Adrenergic vasopressor agents produce systemic vasoconstriction. This increases aortic diastolic pressure, and consequently, coronary and cerebral perfusion pressures. The pharmacologic responses to the adrenergic agents are mediated by a group of receptors that are classified as alpha (), including ₁, and ₂, and beta (ß), including ß₁ and ß₂. Epinephrine, which has each of these adrenergic actions, has been the preferred adrenergic agent for the management of cardiac arrest for almost 40 years. Its primary efficacy is due to its ca-adrenergic vasopressor effects. This contrasts with its ß-adrenergic actions, which are inotropic, chronotropic, and vasodilator. Accordingly,,B-adrenergic actions prompt increases in myocardial oxygen consumption, ectopic ventricular arrhythmias, and transient hypoxemia due to pulmonary arteriovenous shunting. This may account for the failure to demonstrate that epinephrine improves ultimate outcomes in human victims of cardiac arrest. Major interest has more recently been focused on selective -adrenergic agonists. Both ₁,-agonists and ₂-agonists are peripheral vasopressors. However, rapid desensitization of -adrenergic receptors occurs during cardiopulmonary resuscitation. Moreover, ax-adrenergic receptors are present in the myocardium, and ₁-agonists, like ß-adrenergic agonists, increase myocardial oxygen consumption. If they cross the blood-brain barrier, ₂-adrenoceptor agonists also have centrally acting vasodilator effects. In the absence of central nervous system access, ₂-adrenergic agonists have selective peripheral vasoconstrictor effects. Under experimental conditions of cardiopulmonary resuscitation, selective ₂-agonists, which do not gain entrance into the brain, produce only systemic vasoconstriction. Experimentally, these selective Ut₂-agonists are as effective as epinephrine for initial cardiac resuscitation and have the additional advantage of minimizing myocardial oxygen consumption during the global myocardial ischemia of cardiac arrest. Accordingly, myocardial ischemic injury during cardiopulmonary resuscitation is minimized, and postresuscitation myocardial function is preserved with improved survival.

Key Words: cardiac arrest • epinephrine • oc-adrenergic agonist • selective and ß subtypes

Journal of Cardiovascular Pharmacology and Therapeutics, Vol. 8, No. 2, 115-121 (2003)
DOI: 10.1177/107424840300800204


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?